Cancers · 2025
The Emerging Role of Left Atrial Strain in Cardiovascular Risk Stratification for Multiple Myeloma Patients Undergoing Carfilzomib Therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Colomba Anna, Airale Lorenzo, Lasagno Alice, Mingrone Giulia, Astarita Anna, Vallelonga Fabrizio, Leone Dario, Sanapo Martina, Paladino Arianna, Novello Francesca, Bringhen Sara, Gay Francesca, Veglio Franco, Milan Alberto
Аннотация
BACKGROUND: Carfilzomib (CFZ) is a proteasome inhibitor with known cardiotoxic effects used in multiple myeloma (MM) treatment. Cardio-oncology guidelines recommend cardiovascular risk assessment via echocardiography. Left atrial strain (LAS) is not yet included as a marker of cardiotoxicity, but it is emerging as a potential indicator of cardiac dysfunction.
OBJECTIVE: This study evaluates LAS as a predictor of CFZ-related hypertensive cardiovascular adverse events (CVAEs) in MM patients, with or without prior hypertension.
METHODS: A total of 125 MM patients treated with CFZ at the Hypertension Center, "Città della Salute e della Scienza" in Turin, were enrolled. Baseline assessments included transthoracic echocardiography for LAS analysis via Philips QLAB software.
RESULTS: During CFZ therapy, 52% of patients experienced hypertensive events. LAS conduit was significantly impaired in those who experienced CVAEs (-16.20 [-20.75; -12.65] vs. -20.80 [-26.30; -15.40], p = 0.006) and LAS conduit > -22 acted as a predictor of hypertensive adverse events in the normotensive population (OR 2.37 [1.02; 5.50]).
CONCLUSION: These findings indicate that alterations in LAS conduit are linked to an increased risk of hypertensive adverse events during CFZ treatment. Incorporating LAS measurement into cardiovascular risk assessments may improve personalized risk stratification for MM patients, especially those without pre-existing hypertension.
OBJECTIVE: This study evaluates LAS as a predictor of CFZ-related hypertensive cardiovascular adverse events (CVAEs) in MM patients, with or without prior hypertension.
METHODS: A total of 125 MM patients treated with CFZ at the Hypertension Center, "Città della Salute e della Scienza" in Turin, were enrolled. Baseline assessments included transthoracic echocardiography for LAS analysis via Philips QLAB software.
RESULTS: During CFZ therapy, 52% of patients experienced hypertensive events. LAS conduit was significantly impaired in those who experienced CVAEs (-16.20 [-20.75; -12.65] vs. -20.80 [-26.30; -15.40], p = 0.006) and LAS conduit > -22 acted as a predictor of hypertensive adverse events in the normotensive population (OR 2.37 [1.02; 5.50]).
CONCLUSION: These findings indicate that alterations in LAS conduit are linked to an increased risk of hypertensive adverse events during CFZ treatment. Incorporating LAS measurement into cardiovascular risk assessments may improve personalized risk stratification for MM patients, especially those without pre-existing hypertension.